Treatment considerations for elderly and frail patients with neuropathic pain

Mayo Clinic Proceedings

Volumn 85, Issue 3 SUPPL., 2010, Pages

  Schmader, Kenneth E ^a   Baron, Ralf ^b   Haanpää, Maija L ^c,d   Mayer, John ^e   O'Connor, Alec B ^f   Rice, Andrew S C ^g   Stacey, Brett ^h  

^a DURHAM VA MEDICAL CENTER   (United States)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c Rehabilitation ORTON   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

^f UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; BENZODIAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; GABAPENTIN; INSULIN; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PREGABALIN; ANALGESIC AGENT; LOCAL ANESTHETIC AGENT; NARCOTIC AGENT; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

AGED; AGING; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC PAIN; COGNITIVE DEFECT; CONGESTIVE HEART FAILURE; CONSTIPATION; CORONARY ARTERY DISEASE; DAILY LIFE ACTIVITY; DECISION MAKING; DEMENTIA; DIABETES MELLITUS; DIABETIC NEUROPATHY; DISEASE ASSOCIATION; DOCTOR PATIENT RELATION; DRUG SURVEILLANCE PROGRAM; FALLING; FRAIL ELDERLY; FUNCTIONAL STATUS; GASTROESOPHAGEAL REFLUX; GLOMERULUS FILTRATION RATE; HEARING IMPAIRMENT; HERPES ZOSTER; HUMAN; HYPERTENSION; INFLUENZA; INSOMNIA; NEOPLASM; NEUROPATHIC PAIN; OSTEOARTHRITIS; OSTEOPOROSIS; PAIN ASSESSMENT; PARKINSONISM; PHANTOM PAIN; PHYSICAL ACTIVITY; PNEUMONIA; POLYPHARMACY; POSTHERPETIC NEURALGIA; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; STROKE; URINARY TRACT INFECTION; URINE INCONTINENCE; VISUAL IMPAIRMENT; ATTITUDE TO HEALTH; CHRONIC DISEASE; DISEASE MANAGEMENT; FEMALE; GERIATRIC ASSESSMENT; MALE; METHODOLOGY; NEURALGIA; PATIENT EDUCATION;

AGED; AGED, 80 AND OVER; ANALGESICS; ANALGESICS, OPIOID; ANESTHETICS, LOCAL; CHRONIC DISEASE; DISEASE MANAGEMENT; FEMALE; FRAIL ELDERLY; GERIATRIC ASSESSMENT; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; NARCOTIC ANTAGONISTS; NARCOTICS; NEURALGIA; PATIENT EDUCATION AS TOPIC; POLYPHARMACY; RISK FACTORS;

EID: 77950355875     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/mcp.2009.0646     Document Type: Review

References (56)

1. US Census Bureau. International database. Table 094. Midyear population, by age and sex. http://www.census.gov/population/www/projections/natdet-D1A. html. Access April 1, 2009.
2. Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: Redefinition and a grading system for clinical and research purposes. Neurology. 2008;70:1630-1635.
3. McDermott AM, Toelle TR, Rowbotham DJ, Schaefer CP, Dukes EM. The burden of neuropathic pain: results of a cross-sectional survey. Eur J Pain. 2006;10(2):127-135.
4. Schmader KE. The epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain. 2002;18:350-354.
5. Schmader K, Gnann JW Jr, Watson CP. The epidemiological, clinical and pathological rationale for the zoster vaccine. J Infect Dis. 2008;197:S207-S215.
6. Cummins J, Lurie JD, Tosteson TD, et al. Descriptive epidemiology and prior healthcare utilization of patients in the Spine Patient Outcomes Research Trial's (SPORT) three observational cohorts: disc herniation, spinal stenosis, and degenerative spondylolisthesis. Spine. 2006;31:806-814.
7. Ries LAG, Melbert D, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD, based on November 2007 SEER data submission, posted to the SEER Web site, 2008. http://seer.cancer.gov/csr/1975-2005/index.html. Accessed January 11, 2010.
8. Dillingham TR, Pezzin LE, MacKenzie EJ. Limb amputation and limb deficiency: epidemiology and recent trends in the United States. South Med J. 2002;95(8):875-883.
9. Pleis JR, Lethbridge-çejku M. Summary health statistics for U.S. adults: National Health Interview Survey, 2006. Vital Health Stat 10. 2007 Dec;(235):1-153.
10. Hall GC, Carroll D, Parry D, McQuay HJ. Epidemiology and treatment of neuropathic pain: the UK primary care perspective. Pain. 2006;122(1-2):156-162.
11. Nelson EA, Dannefer D. Aged heterogeneity: fact or fiction? the fate of diversity in gerontological research. Gerontologist. 1992;32:17-23.
12. Rowe JW, Kahn RL. Human aging: usual and successful. Science. 1987;237:143-149.
13. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146.
14. Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G. Untangling the concepts of disability, frailty and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci. 2004;59(3):255-263.
15. Ferrucci L, Guralnik JM, Studenski S, et al; Interventions on Frailty Working Group. Designing randomized, controlled trials aimed at preventing or delaying functional decline and disability in frail older persons: a consensus report. J Am Geriatr Soc. 2004;52:625-634.
16. Wenger NS, Shekelle PG; ACOVE Investigators. Assessing care of vulnerable elders: ACOVE project overview. Ann Intern Med. 2001;135:642-646.
17. van den Akker M, Buntinx F, Roos S, et al. Problems in determining occurrence rates of multimorbidity. J Clin Epidemiol. 2001;54:675-679.
18. Crimmins EM. Trends in the health of the elderly. Annu Rev Public Health. 2004;25:79-98.
19. Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med. 2002;162:2269-2276.
20. Fortin M, Bravo G, Hudon C, et al. Prevalence of multimorbidity among adults seen in family practice. Ann Fam Med. 2005;3:223-228.
21. Britt HC, Harrison CM, Miller GC, Knox SA. Prevalence and patterns of multimorbidity in Australia. Med J Aust. 2008;189:72-77.
22. Berger A, Dukes EM, Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain. 2004;5:143-149.
23. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged: the index of ADL: a standardized measure of biological and psychosocial function. JAMA. 1963;185:914-919.
24. Fillenbaum GG. Screening the elderly: a brief instrumental activities of daily living measure. J Am Geriatr Soc. 1985;33(10):698-706.
25. Adams PF, Barnes PM, Vickerie JL. Summary health statistics for the U.S. population: National Health Interview Survey, 2007. Vital Health Stat 10. 2008 Nov;(238):1-104.
26. Meyer-Rosberg K, Kvarnstrom A, Kinnman E, et al. Peripheral Neuropathic Pain - a multidimensional burden for patients. Eur J Pain. 2001;5:379-389.
27. Gustorff B, Dorner T, Likar R, et al. Prevalence of self-reported neuropathic pain and impact on quality of life: a prospective representative survey. Acta Anaesthesiol Scand. 2008;52(1):132-136.
28. Katz J, Cooper EM, Walther RR, Sweeney EW, Dworkin RH. Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis. 2004;39:342-348.
29. Schmader KE, Sloane R, Pieper C, et al. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain. 2007;23:490-497.
30. Oster G, Harding G, Dukes E, Edelsberg J, Cleary PD. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain. 2005;6(6):356-363.
31. Gore M, Brandenburg NA, Dukes E, Hoffman DL, Tai KS, Stacey B. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage. 2005;30(4):374-385.
32. Jensen MP, Chodroff MJ, Dworkin RH. The impact of neuropathic pain on health-related quality of life: review and implications. Neurology. 2007;68:1178-1182.
33. O'Connor AB. Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy. Pharmacoeconomics. 2009;27:95-112.
34. Sofaer-Bennett B, Walker J, Moore A, Lamberty J, Thorp T, O'Dwyer J. The social consequences for older people of neuropathic pain: a qualitative study. Pain Med. 2007;8(3):263-270. (Pubitemid 46443466)
35. Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005;113:9-19.
36. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994;23(2):129-138.
37. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA. 2002;287:337-344.
38. Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008;300(24):2867-2878.
39. Perkins NA, Murphy JE, Malone DC, Armstrong EP. Performance of drug-drug interaction software for personal digital assistants. Ann Pharmacother. 2006;40:850-855.
40. Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289:1107-1116.
41. Gurwitz JH, Field TS, Avorn J, et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med. 2000;109:87-94.
42. Budnitz DS, Shehab N, Kegler SR, Richards CL. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med. 2007;147:755-765.
43. Schmader KE, Hanlon JT, Pieper CF, et al. Effectiveness of geriatric evaluation and management on adverse drug reactions and suboptimal prescribing in the frail elderly. Am J Med. 2004;116:394-401.
44. Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people: the prescribing cascade. BMJ. 1997;315:1096-1099.
45. Higashi T, Shekelle PG, Solomon DH, et al. The quality of pharmacologic care for vulnerable older patients. Ann Intern Med. 2004;140:714-720.
46. Cusak BJ. Pharmacokinetics in older persons. Am J Geriatr Pharmacother. 2004;2(4):274-302.
47. Bowie MW, Slattum PW. Pharmacodynamics in older adults: a review. Am J Geriatr Pharmacother. 2007;5:263-303.
48. Bugeja G, Kumar A, Banerjee AK. Exclusion of elderly people from clinical research: a descriptive study of published reports. BMJ. 1997;315:1059.
49. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341:2061-2067.
50. Lee PY, Alexander KP, Hammill BG, Pasquali SK, Peterson ED. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA. 2001;286:708-713.
51. Le Quintrec JL, Bussy C, Golmard JL, HervÉ C, Baulon A, Piette F. Randomized controlled drug trials on very elderly subjects: descriptive and methodological analysis of trials published between 1990 and 2002 and comparison with trials on adults. J Gerontol A Biol Med Sci. 2005;60(3):340-344.
52. US Government Accountability Office (GAO). Prescription Drugs: FDA Guidance and Regulations Related to Data on Elderly Persons in Clinical Drug Trials. GAO-07-47R, September 28, 2007. www.gao.gov/products/GAO-07-47R. Accessed January 11, 2010.
53. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebocontrolled trial. Pain. 2004;110:628-638.
54. Sabatowski R, Galvez R, Cherry DA, et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain. 2004;109:26-35.
55. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment postherpetic neuralgia: a randomized controlled trial. JAMA. 1998;280(21):1837-1842.
56. Witham MD, McMurdo ME. How to get older people included in clinical studies. Drugs Aging. 2007;24:187-196. (Pubitemid 46457023)